Scarica l'app Stockscreener
19.82
0.35%
0.07
Dopo l'orario di chiusura:
19.82
Precedente Chiudi:
$19.75
Aprire:
$19.78
Volume 24 ore:
263.76K
Relative Volume:
0.57
Capitalizzazione di mercato:
$1.00B
Reddito:
$62.02M
Utile/perdita netta:
$-45.65M
Rapporto P/E:
-21.54
EPS:
-0.92
Flusso di cassa netto:
$-9.60M
1 W Prestazione:
-2.94%
1M Prestazione:
+5.20%
6M Prestazione:
+79.69%
1 anno Prestazione:
+104.96%
Intervallo 1D:
$19.58
$20.02
Intervallo di 1 settimana:
$19.50
$21.03
Portata 52W:
$7.90
$21.03
Theravance Biopharma Inc Stock (TBPH) Company Profile
Nome
Theravance Biopharma Inc
Settore
Industria
Telefono
650-808-6000
Indirizzo
UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN
Confronta TBPH con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TBPH
Theravance Biopharma Inc
|
19.82 | 1.00B | 62.02M | -45.65M | -9.60M | -0.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Theravance Biopharma Inc Stock (TBPH) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-03 | Iniziato | Oppenheimer | Outperform |
| 2025-09-12 | Iniziato | B. Riley Securities | Buy |
| 2024-08-06 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-04-12 | Iniziato | BTIG Research | Buy |
| 2024-01-08 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2021-11-05 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2021-09-15 | Downgrade | JP Morgan | Overweight → Underweight |
| 2021-08-25 | Downgrade | Morgan Stanley | Overweight → Underweight |
| 2021-08-24 | Downgrade | Cowen | Outperform → Market Perform |
| 2020-10-14 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-07-07 | Iniziato | JP Morgan | Overweight |
| 2020-06-15 | Iniziato | Morgan Stanley | Equal-Weight |
| 2020-05-13 | Iniziato | Cowen | Outperform |
| 2020-01-08 | Reiterato | H.C. Wainwright | Buy |
| 2019-11-06 | Aggiornamento | Robert W. Baird | Underperform → Neutral |
| 2019-10-29 | Iniziato | H.C. Wainwright | Buy |
| 2018-03-29 | Ripresa | Piper Jaffray | Overweight |
| 2017-08-17 | Iniziato | Evercore ISI | Outperform |
| 2017-06-16 | Iniziato | Cantor Fitzgerald | Overweight |
| 2017-05-11 | Reiterato | Needham | Buy |
| 2016-12-21 | Iniziato | Needham | Buy |
| 2016-11-03 | Iniziato | Piper Jaffray | Overweight |
| 2016-10-12 | Downgrade | Robert W. Baird | Neutral → Underperform |
| 2016-08-03 | Downgrade | BofA/Merrill | Neutral → Underperform |
| 2016-06-20 | Iniziato | Guggenheim | Buy |
| 2016-06-20 | Reiterato | Leerink Partners | Outperform |
| 2016-05-12 | Iniziato | Leerink Partners | Outperform |
| 2016-05-05 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2015-02-03 | Aggiornamento | Robert W. Baird | Underperform → Neutral |
Mostra tutto
Theravance Biopharma Inc Borsa (TBPH) Ultime notizie
Technical Reactions to TBPH Trends in Macro Strategies - Stock Traders Daily
Why Theravance Biopharma (TBPH) is a Top Momentum Stock for the Long-Term - Yahoo Finance
Profit Review: Is Theravance Biopharma Inc affected by consumer sentimentSell Signal & Safe Entry Zone Identification - baoquankhu1.vn
Theravance Biopharma, Inc. (TBPH) Investor Outlook: Unveiling A 28.81% Potential Upside - directorstalkinterviews.com
Theravance Biopharma stock hits 52-week high at $21.01 By Investing.com - Investing.com Nigeria
Theravance Biopharma stock hits 52-week high at $21.01 - Investing.com
Theravance Biopharma (NASDAQ:TBPH) Reaches New 1-Year HighHere's What Happened - MarketBeat
Neurogenic Orthostatic Hypotension (nOH) Global Clinical Trials Market Review 2025: Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End Point Status - GlobeNewswire Inc.
Why Theravance Biopharma (TBPH) is a Top Growth Stock for the Long-Term - sharewise.com
Theravance Biopharma, Inc. (NASDAQ:TBPH) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
Theravance Biopharma stock hits 52-week high at 20.69 USD By Investing.com - Investing.com Nigeria
Theravance Biopharma stock hits 52-week high at 20.69 USD - Investing.com
Trading the Move, Not the Narrative: (TBPH) Edition - Stock Traders Daily
Theravance Biopharma (NASDAQ:TBPH) Sets New 12-Month HighWhat's Next? - MarketBeat
Theravance Biopharma CEO earns 2026 Honorable Mentor title - Traders Union
Theravance Biopharma, Inc. Announces Upcoming Phase 3 Data for Ampreloxetine - TradingView — Track All Markets
Theravance Biopharma, Inc. (TBPH) Stock Analysis: Unpacking A 40% Potential Upside - DirectorsTalk Interviews
What valuation ratios show for Theravance Biopharma Inc. (0TB) stockJuly 2025 Technicals & Reliable Entry Point Alerts - Улправда
Chart Watch: What valuation ratios show for Theravance Biopharma Inc. (0TB) stockWeekly Trend Recap & Smart Investment Allocation Tips - Улправда
Will Theravance Biopharma Inc. stock deliver better than expected guidanceMarket Activity Summary & Verified Momentum Stock Ideas - Улправда
Published on: 2026-01-08 18:37:29 - Улправда
mF International, Theravance Biopharma And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Theravance Biopharma (NASDAQ:TBPH) Share Price Crosses Above Fifty Day Moving AverageWhat's Next? - MarketBeat
Theravance Biopharma (NASDAQ:TBPH) Share Price Crosses Above Fifty Day Moving Average – What’s Next? - Defense World
(TBPH) Volatility Zones as Tactical Triggers - Stock Traders Daily
Theravance Biopharma (NASDAQ:TBPH) Lowered to Buy Rating by Wall Street Zen - MarketBeat
Portfolio Update: Why Theravance Biopharma Inc 0TB stock stays resilient2025 Short Interest & Daily Entry Point Alerts - moha.gov.vn
Can Theravance Biopharma's Ampreloxetine Fill The Gap In MSA-Related NOH Therapy? - RTTNews
Market Overview: Is Theravance Biopharma Inc stock trading near support levels2025 Macro Impact & Weekly Return Optimization Plans - Bộ Nội Vụ
What drives Theravance Biopharma Inc stock priceMarket Insider Reports & Build Your Portfolio With Our Free Stock Scanner - earlytimes.in
Inspire Investing LLC Purchases New Position in Theravance Biopharma, Inc. $TBPH - MarketBeat
Here's Why Theravance Biopharma (TBPH) is a Strong Growth Stock - sharewise.com
(TBPH) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Wall Street Analysts Believe Theravance Bio (TBPH) Could Rally 42.15%: Here's is How to Trade - Finviz
Assenagon Asset Management S.A. Boosts Position in Theravance Biopharma, Inc. $TBPH - MarketBeat
Theravance Biopharma, Inc. (NASDAQ:TBPH) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
With Theravance Biopharma Stock Surging, Have You Considered The Downside? - Trefis
Why Theravance Biopharma Inc. stock could outperform in 2025Portfolio Return Report & Verified Entry Point Detection - Улправда
How Theravance Biopharma Inc. stock reacts to global recession fears2025 Market WrapUp & AI Driven Stock Movement Reports - Улправда
How Theravance Biopharma Inc. stock reacts to Fed rate cuts2025 Major Catalysts & Real-Time Volume Triggers - Улправда
Will Theravance Biopharma Inc. stock outperform Dow Jones indexMarket Movement Recap & Weekly Stock Breakout Alerts - Улправда
Is Theravance Biopharma Inc. stock trading near support levelsWeekly Market Outlook & Free Expert Verified Stock Movement Alerts - DonanımHaber
Will Theravance Biopharma Inc. stock attract ESG investorsMarket Growth Report & Free Community Consensus Stock Picks - DonanımHaber
Is Theravance Biopharma Inc. (0TB) stock a buy before new product rolloutJuly 2025 Earnings & Short-Term Swing Trade Alerts - DonanımHaber
Theravance Biopharma, Inc. (TBPH) Stock Analysis: Unveiling a 46.94% Potential Upside for Investors - DirectorsTalk Interviews
Theravance Biopharma, Inc. (TBPH) Discusses Ampreloxetine Phase 3 Program and Unmet Need in Neurogenic Orthostatic Hypotension with Multiple System AtrophySlideshow (NASDAQ:TBPH) 2025-12-15 - Seeking Alpha
Theravance Biopharma (NASDAQ:TBPH) Stock Rating Upgraded by Wall Street Zen - MarketBeat
History Review: How Theravance Biopharma Inc. stock reacts to global recession fearsRate Hike & Scalable Portfolio Growth Methods - moha.gov.vn
Why The Narrative Around Theravance Biopharma Is Shifting After Trelegy Monetization And Strategic Review - Yahoo Finance
Camber Capital Management LP Trims Stock Position in Theravance Biopharma, Inc. $TBPH - MarketBeat
Theravance Biopharma Inc Azioni (TBPH) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.09%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):